Alkermes Incorporated

Alkermes, Inc. is applying the tools of biotechnology to the development of sophisticated proprietary drug delivery systems. Alkermes is developing product candidates based on its independent drug delivery technologies: ProLease(R), which is designed to enable single injections lasting a few days to several months to be made of proteins or peptides otherwise given by more frequent injection; Cereport(TM) (formerly known as RMP-7(TM)), which is designed to enable increased drug delivery to the brain by transiently opening the blood-brain barrier; and Medisorb(R), which extends Alkermes' technology for injectable sustained release and is designed for more traditional small molecule pharmaceutical compounds.

Contact Details: 64 Sidney Street Cambridge MA 02139-4234 United States of America Tel: 617 494 0171 Fax: 617 494 9263 Email: financial@alkermes.com WWW: www.alkermes.com/

Loading...

Recent Publications by Alkermes Incorporated:
Overriding the blockade of antinociceptive actions of opioids in rats treated with extended-release naltrexone. A monthly extended-release formulation of the opioid antagonist naltrexone...	7th August, 2008	Department of Life Sciences and Toxicology, Alkermes, Inc., 88 Sidney St.,	Pharmacol Biochem Behav. 2008 Jun;89(4):515-22. Epub 2008 Feb 11. DOI Direct Link
Inhaled insulin for controlling blood glucose in patients with diabetes. Diabetes mellitus is a significant worldwide health problem, with the...	26th February, 2008	Alkermes, Inc, Cambridge, MA, USA.	Vasc Health Risk Manag. 2007;3(6):947-58.
Population pharmacokinetics of extended-release injectable naltrexone (XR-NTX) in patients with alcohol dependence. OBJECTIVE: Injectable extended-release naltrexone (XR-NTX; Vivitrol) has...	30th January, 2008	Alkermes, Inc., 88 Sidney Street, Cambridge, Massachusetts 02139, USA.	J Stud Alcohol Drugs. 2007 Nov;68(6):862-70.
A feasibility study of a web-based performance improvement system for substance abuse treatment providers. We report here on the feasibility of implementing a semiautomated...	18th January, 2008	Alkermes Inc., Boston, MA, USA.	J Subst Abuse Treat. 2007 Dec;33(4):363-71. Epub 2007 May 14. DOI Direct Link
Reduction in heavy drinking as a treatment outcome in alcohol dependence. In the field of clinical alcohol disorders treatment in North America,...	16th October, 2007	Alkermes,	J Subst Abuse Treat. 2007 Jul;33(1):71-80. Epub 2007 Feb 22. DOI Direct Link
→View more Alkermes Incorporated research publications.

BioNews Results for Alkermes Incorporated:
High Growth Reported for the World Pulmonary Drug Delivery Technologies Market	Houston Chronicle:  Oct 2 2008 1:25AM Matching: alkermes
High Growth Reported for the World Pulmonary Drug Delivery Technologies Market	NewsBlaze:  Oct 1 2008 11:34PM Matching: alkermes
Reportlinker.com: High Growth Reported for the World Pulmonary Drug Delivery Technologies Market	Market Wire:  Oct 1 2008 10:38PM Matching: alkermes
High Growth Reported for the World Pulmonary Drug Delivery Technologies Market	Market Wire:  Oct 1 2008 10:31PM Matching: alkermes
High Growth Reported for the World Pulmonary Drug Delivery Technologies Market	Yahoo! Canada:  Oct 1 2008 10:28PM Matching: alkermes
Promote your company here: BioNewsCast - Press Release Distribution	→View more Alkermes Incorporated news.

Alkermes Incorporated Patents:
US Patent No.	Title
6428815	Method of producing sub-micron particles of biologically active agents and uses thereof
6544559	Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
6555525	Microencapsulation and sustained release of oligonucleotides
6558702	Method of modifying the release profile of sustained release compositions
6565888	Methods and compositions for the targeted delivery of biologically active agents
→View more Alkermes Incorporated patents.

Alkermes Incorporated (ALKS) Financial information Links from Barchart
ALKS Quote from from Barchart.com
ALKS Chart from from Barchart.com
ALKS Profile from from Barchart.com
ALKS Opinion from from Barchart.com
→View more Alkermes Incorporated finance information.

BioPortfolio Ltd provides targeted e-mail address lists for the life science sector - we can enable you to contact around 26 individuals from Alkermes Incorporated using this service.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 183 times since April 2007, the link to the organisation's website has been followed 43 times

Recent Search Terms used to find this page: @alkermes.com | alkermes | .

Search for more companies in Cambridge

Search for more companies in MA

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Alkermes Incorporated